Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Analysts say the delay is most likely administrative and that the overall plan is still on track.
China’s falling fertility rate sees spike in demand for assisted reproduction as biotech firm raises US$101 million from Hong Kong listing.
Reaching development, regulatory and commercial milestones could see value of deal hit around US$2.75 billion.
Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.
Advertisement
All 123 units at Chester were sold, with strong demand pointing to a steady recovery in Hong Kong’s residential sector.
Hong Kong government-backed investor says strong returns and co-investment flows are reinforcing the region’s appeal to global capital.
Hospital-network operator delays plan to raise up to US$115 million amid tepid demand.
Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.
Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.
Advanced manufacturing and healthcare attract more attention at the expense of technology, media and telecommunications, Bain & Co says.
Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.
Oversight of China’s industry intensifies, with carmakers urged to move beyond discounts and focus on chips and self-driving systems.
Booming listings and rising outbound investment demand are accelerating growth for Chinese players, SFC data shows.
Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.
More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.
China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.
Agency says limited exposure to the Middle East has kept trade risks contained for most Hong Kong exporters.
US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.
Survey shows family offices expanding risk management while maintaining strong investment exposure to Hong Kong and Asia.
Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.
Hong Kong-listed biotech firm’s shares jump after announcing partnership to use AI tools in drug discovery in the United Arab Emirates.
Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says.
The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.
Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.
Modelled on Stock Connect, the proposal would give investors in the Greater Bay Area cross-border access to new share listings.
Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.
After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.
Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.
The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.
